Abstract
Lipid nanoparticles (LNPs) have emerged as a promising platform for targeted drug delivery in cancer therapy due to their biocompatibility, ability to encapsulate a wide range of therapeutic agents, and potential for enhancing the bioavailability and stability of drugs. LNPs are particularly valuable for the delivery of poorly soluble anticancer drugs, nucleic acids, and gene therapies. This article explores the role of lipid nanoparticles in cancer treatment, their mechanisms of action, and the ongoing advancements in their design and application. Challenges such as stability, scale-up production, and regulatory approval are also discussed. Furthermore, the future prospects for LNP-based cancer therapies are examined, highlighting the need for personalized approaches to optimize treatment outcomes.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Dr. Sarah Ahmad (Author)